@article{b5c5b023485943898bac2b00b476c96c,
title = "Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study",
keywords = "Multiple sclerosis, alemtuzumab, efficacy, induction, ocrelizumab, safety, therapy, Multiple sclerosis, alemtuzumab, efficacy, induction, ocrelizumab, safety, therapy",
author = "Caterina Lapucci and Jessica Frau and Eleonora Cocco and Giancarlo Coghe and Maria Petracca and Roberta Lanzillo and \{Brescia Morra\}, Vincenzo and Nicoletti, \{Carolina Gabri\} and Doriana Landi and Girolama Marfia and Marco Vercellino and Paola Cavalla and Assunta Bianco and Massimiliano Mirabella and \{Torri Clerici\}, Valentina and Eugenia Tomas and Ferr{\`o}, \{Maria Teresa\} and Paola Grossi and Agostino Nozzolillo and Lucia Moiola and Mauro Zaffaroni and Marco Ronzoni and Federica Pinardi and Giovanni Novi and Maria Cellerino and Antonio Uccelli and Matilde Inglese",
year = "2024",
doi = "10.1177/13524585241266509",
language = "English",
volume = "30",
pages = "N/A--N/A",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
}